Treatment of Acute Bacterial Prostatitis
For acute bacterial prostatitis, prescribe fluoroquinolones (ciprofloxacin 500-750 mg orally twice daily) for 2-4 weeks if local resistance is <10%, or use intravenous ceftriaxone plus doxycycline for hospitalized patients with severe illness. 1, 2, 3
Outpatient vs. Inpatient Decision Algorithm
Hospitalize patients who:
- Cannot tolerate oral medications 1
- Show signs of systemic toxicity or risk of urosepsis (occurs in 7.3% of cases) 1
- Have suspected prostatic abscess 1
- Present with fever, chills, nausea, emesis, or malaise suggesting systemic illness 4
Treat as outpatient if:
- Patient can tolerate oral medications 1
- Mild-to-moderate symptoms without fever 1
- No risk factors for antibiotic resistance 1
First-Line Antibiotic Regimens
For Outpatient Treatment (Mild-to-Moderate Cases):
- Ciprofloxacin 500-750 mg orally twice daily for 2-4 weeks (92-97% success rate) 1, 3
- Only use if local fluoroquinolone resistance is <10% 1, 2
- Avoid if patient received fluoroquinolones in the last 6 months 1, 2
For Hospitalized Patients (Severe Cases):
- Ceftriaxone IV plus doxycycline 2, 4
- Piperacillin-tazobactam IV 3, 4
- Ciprofloxacin 400 mg IV twice daily, then switch to oral once clinically improved 1
Alternative Options When Fluoroquinolones Cannot Be Used:
- Avoid trimethoprim-sulfamethoxazole empirically unless organism is known to be susceptible (high resistance rates) 1
- Avoid amoxicillin/ampicillin empirically due to very high worldwide resistance rates (75% median E. coli resistance) 1, 2
Essential Diagnostic Steps Before Treatment
Obtain these tests in all patients:
- Midstream urine culture (identifies causative organism in most cases) 1, 2
- Blood cultures, especially if febrile 1, 2
- Complete blood count to assess for leukocytosis 1, 2
Physical examination findings:
- Perform gentle digital rectal examination to assess for tender, enlarged, or boggy prostate 4
- Avoid vigorous prostatic massage or vigorous digital rectal examination due to risk of bacteremia and sepsis 1, 2
Additional imaging if indicated:
Microbiology and Resistance Considerations
Common pathogens:
- Gram-negative bacteria cause 80-97% of cases: E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa 1
- Gram-positive bacteria: Staphylococcus aureus, Enterococcus species, Group B streptococci 1
For healthcare-associated infections with enterococci:
- Use ampicillin, piperacillin-tazobactam, or vancomycin based on susceptibility 1
- Consider carbapenems or novel broad-spectrum agents only when early culture results indicate multidrug-resistant organisms 1
Special Population: Men Under 35 Years
Add coverage for sexually transmitted pathogens:
- Doxycycline 100 mg orally every 12 hours for 7 days to cover Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma species 1
- Alternative: Azithromycin 1 g orally as single dose for Mycoplasma coverage 1
- Treat all sexual partners within preceding 60 days 1
- Abstain from sexual activity until 7 days after initiating therapy and symptoms resolve 1
Treatment Duration and Follow-Up
Duration:
- Minimum 2-4 weeks for acute bacterial prostatitis 1, 2, 3
- Completing the full course is critical—premature discontinuation can lead to chronic bacterial prostatitis 1
Reassessment:
- Assess clinical response after 48-72 hours of treatment 1
- Adjust antibiotics based on culture and susceptibility results 1
Critical Pitfalls to Avoid
- Never perform vigorous prostatic massage in acute prostatitis—this can cause bacteremia 1, 2
- Do not use oral cephalosporins (e.g., cefpodoxime) for prostatitis—they have poor prostatic tissue penetration despite efficacy in pyelonephritis 1
- Do not stop antibiotics early—inadequate treatment duration leads to chronic bacterial prostatitis with lifelong recurrent UTIs 1, 5
- Do not use fluoroquinolones empirically if local resistance >10% 1, 2
- Do not overlook underlying conditions—acute bacterial prostatitis is rare in healthy men; consider benign prostatic hyperplasia, urinary stones, malignancy, or sexually transmitted diseases 5